Epratuzumab Reduced Disease Activity And Steroid Use In Patients With Moderate And Severe Flaring SLE
Added: 18 июня 2008
Last relative articles:
- Stroke Study Reveals Key Target For Improving Treatment
- Bowel Prep Oral Sodium Phosphate Equal To Fasting Before Capsule Endoscopy For Obscure GI Bleeding
- Poor Children More Likely To Develop Diabetes As Adults
- Forest Laboratories Announces Positive Results From Phase III Clinical Studies Of Ceftaroline For The Treatment Of Complicated Skin And Skin Structure
- US WorldMeds Completes Phase III Trial Of Lofexidine For Treatment Of Opiate Withdrawal Symptoms
- Long-Term Safety Data On Lialda TM mesalamine For Patients With Ulcerative Colitis Published In Leading GI Journal
- Two-Year Clinical Trial Findings Show Significant And Persistent Reduction In Blood Pressure With CVRx R Rheos R Hypertension Therapy
- New Technology May Prevent Vitamin B12 Deficient Seniors And Vegetarians From Needing Injections
- Long-Term Safety Data On Lialda Published In Leading GI Journal
- Vascular Damage Effectively Reversed Using Hypertension Treatment
Comments: [0] / Post comment:
07 Jan 2009 21:05:05
Immunomedics to Present at 27th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
Immunomedics to Present at 27th Annual JP Morgan Healthcare Conference PR Newswire (press release), NY - ... our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications ...
07 Jan 2009 18:44:58
Research and Markets: In 2007, Sales of Agents Used To Treat ... - MarketWatch (press release)
Research and Markets: In 2007, Sales of Agents Used To Treat ... MarketWatch (press release) - ... azathioprine Emerging therapies: Biogen Idec Genentech Chugai Pharmaceutical Zenyaku Kogyo Roche's Rituxan MabThera, UCB Immunomedic's epratuzumab , ...
19 Dec 2008 18:41:05
Immunomedics' hPAM4 Labeled With Yttrium-90 Receives Orphan ... - Trading Markets (press release)
Immunomedics' hPAM4 Labeled With Yttrium-90 Receives Orphan ... Trading Markets (press release), CA - ... our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications ...
16 Dec 2008 15:30:30
High Growth Forecasted for the World Monoclonal Antibody Based ... - MarketWatch
High Growth Forecasted for the World Monoclonal Antibody Based ... MarketWatch - ... Vs. Epratuzumab II-8 A Revolution Not too Far II-9 Milestones in Development of MAbs II-9 Focus on Unmet Medical Needs in the Emerging Markets II-9 2. ...
12 Dec 2008 13:07:47
Epratuzumab Plus Rituximab Effective in Recurrent NHL - Cancerpage.com
Epratuzumab Plus Rituximab Effective in Recurrent NHL Cancerpage.com, GA - By Martha Kerr NEW YORK DEC 11, 2008 (Reuters Health) - Combination therapy with the anti-CD22 monoclonal antibody epratuzumab and the anti-CD20 monoclonal ...